Tocilizumab is the only interleukin-6 receptor antagonist available for both subcutaneous and intravenous administration in RA. The 162mg prefilled syringe for subcutaneous administration can be used both as monotherapy and in combination with methotrexate or other DMARDs.
"The versatility that RoActemra now offers is extremely valuable to the patient, not to mention the freeing up of precious consulting time for clinicians," said Professor Choy, Professor of Rheumatology at the Cardiff Institute of Infection & Immunity.
The SUMMACTA study showed that the efficacy of subcutaneous tocilizumab was comparable to that of the intravenous formulation. The adverse event profiles of the subcutaneous and intravenous formulations were also comparable, with the exception of a higher incidence of injection site reactions observed with the subcutaneous injection.
Further information: Roche